keyword
MENU ▼
Read by QxMD icon Read
search

Fotemustine

keyword
https://www.readbyqxmd.com/read/30109672/fotemustine-teniposide-and-dexamethasone-versus-high-dose-methotrexate-plus-cytarabine-in-newly-diagnosed-primary-cns-lymphoma-a-randomised-phase-2-trial
#1
Jingjing Wu, Lingling Duan, Lei Zhang, Zhenchang Sun, Xiaorui Fu, Xin Li, Ling Li, Xinhua Wang, Xudong Zhang, Zhaoming Li, Hui Yu, Yu Chang, Feifei Nan, Jiaqin Yan, Li Tian, Xiaoli Wang, Mingzhi Zhang
OBJECTIVE: This prospective, randomized, controlled and open-label clinical trial sought to evaluate the tolerability and efficacy of the FTD regimen (fotemustine, teniposide and dexamethasone) compared to HD-MA therapy (high-dose methotrexate plus cytarabine) and to elucidate some biomarkers that influence outcomes in patients with newly diagnosed primary CNS lymphoma. METHODS: Participants were stratified by IELSG risk score (low versus intermediate versus high) and randomly assigned (1:1) to receive four cycles of FTD or HD-MA regimen...
August 14, 2018: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29979390/high-dose-fotemustine-in-temozolomide-pretreated-glioblastoma-multiforme-patients-a-phase-i-ii-trial
#2
Alfredo Marinelli, Giuseppe Lamberti, Luigi Cerbone, Nadia Cordua, Carlo Buonerba, Gianfranco Peluso, Giuseppe Di Lorenzo, Sabino De Placido
BACKGROUND: Glioblastoma multiforme (GBM) is a rare and deadly disease, with a reported average incidence rate of 3.19 cases per 100,000 inhabitants. Fotemustine, a third-generation nitrosourea with an alanine phosphor carrier that facilitates cellular penetration, has been extensively investigated in the setting of recurrent/progressive disease after initial treatment. Fotemustine is usually administered following a schedule consisting of 3 doses every week, followed by maintenance doses administered every 3 weeks...
July 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29899845/a-novel-combinatorial-treatment-option-for-metastatic-uveal-melanoma
#3
Dudi Shneor, Shay Tayeb, Jacob Pe'er, Hanna Voropaev, Maria Gimmelshein, Nathalie Cassoux, Alik Honigman, Shahar Frenkel
Uveal melanoma (UM) is the most frequent intraocular tumor in adult patients. When metastases occur, systemic therapy with alkylating agents (fotemustine or dacarbazine (DTIC)) has shown only modest efficacy. The common chemotherapeutic drug doxorubicin (DOX) is not used to treat metastatic UM (mUM). To expand the chemotherapeutic arsenal for mUM, we tested the effect of DOX on UM cell mortality. We have previously shown that CREB knockdown enhances sensitivity to DOX. UM cells infected with recombinant MuLV-based replicative competent retroviruses (RCR) expressing shRNA targeting CREB were co-treated with either DTIC or DOX...
May 25, 2018: Oncotarget
https://www.readbyqxmd.com/read/29782366/single-agent-bevacizumab-in-recurrent-glioblastoma-after-second-line-chemotherapy-with-fotemustine-the-experience-of-the-italian-association-of-neuro-oncology
#4
Francesco Pasqualetti, Andrea Pace, Alessandra Gonnelli, Veronica Villani, Martina Cantarella, Durim Delishaj, Caterina Vivaldi, Alessandro Molinari, Sabrina Montrone, Alessia Pellerino, Federica Franchino, Davide Baldaccini, Giuseppe Lombardi, Ivan Lolli, Francesca Catania, Elena Bazzoli, Riccardo Morganti, Alessandra Fabi, Vittorina Zagonel, Guido Bocci, Maria Grazia Fabrini, Roberta Rudà, Riccardo Soffietti, Fabiola Paiar
OBJECTIVES: Bevacizumab is an anti-vascular endothelial growth factor antibody used in the treatment of recurrent glioblastoma (GBM). Despite the large number of studies carried out in patients with recurrent GBM, little is known about the administration of this angiogenesis inhibitor after the failure of the second-line chemotherapy. MATERIALS AND METHODS: In this retrospective multicenter study, on behalf of the Italian Association of Neuro-Oncology, we reported the results obtained in 51 patients with recurrent GBM treated with single-agent bevacizumab after the failure of second-line chemotherapy with fotemustine...
May 18, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29747595/the-search-for-a-melanoma-tailored-chemotherapy-in-the-new-era-of-personalized-therapy-a-phase-ii-study-of-chemo-modulating-temozolomide-followed-by-fotemustine-and-a-cooperative-study-of-goim-gruppo-oncologico-italia-meridionale
#5
Michele Guida, Stefania Tommasi, Sabino Strippoli, Maria Iole Natalicchio, Simona De Summa, Rosamaria Pinto, Antonio Cramarossa, Anna Albano, Salvatore Pisconti, Michele Aieta, Ruggiero Ridolfi, Amalia Azzariti, Gabriella Guida, Vito Lorusso, Giusepe Colucci
BACKGROUND: It is frequently asked whether chemotherapy can still play a role in metastatic melanoma considering the effectiveness of the available drugs today, including antiCTLA4/antiPD1 immunotherapy and antiBRAF/antiMEK inhibitors. However, only approximately half of patients respond to these drugs, and the majority progress after 6-11 months. Therefore, a need for other therapeutic options is still very much apparent. We report the first large trial of a sequential full dose of fotemustine (FM) preceded by a low dose of temozolomide (TMZ) as a chemo-modulator in order to inactivate the DNA repair action of O(6)-methylguanine DNA-methyltransferase (MGMT)...
May 10, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29552321/combined-vemurafenib-and-fotemustine-in-patients-with-braf-v600-melanoma-progressing-on-vemurafenib
#6
Paola Queirolo, Francesco Spagnolo, Virginia Picasso, Laura Spano, Enrica Tanda, Valeria Fontana, Laura Giorello, Domenico Franco Merlo, Ester Simeone, Antonio Maria Grimaldi, Marcello Curvietto, Michele Del Vecchio, Paolo Bruzzi, Paolo Antonio Ascierto
Background: BRAF inhibitor vemurafenib achieves high response rate and an improvement in survival in patients with BRAF-mutated metastatic melanoma. However, median progression-free survival is only 6.9 months in the phase 3 study. Retrospective analyses suggest that treatment with BRAF inhibitors beyond initial progression might be associated with improved overall survival. We aimed to prospectively investigate the activity of prolonged treatment with vemurafenib and the addition of fotemustine in patients with systemic progression on prior single-agent BRAF inhibitor...
February 23, 2018: Oncotarget
https://www.readbyqxmd.com/read/29100281/recq1-expression-is-upregulated-in-response-to-dna-damage-and-in-a-p53-dependent-manner
#7
Swetha Parvathaneni, Xing Lu, Ritu Chaudhary, Ashish Lal, Srinivasan Madhusudan, Sudha Sharma
Sensitivity of cancer cells to DNA damaging chemotherapeutics is determined by DNA repair processes. Consequently, cancer cells may upregulate the expression of certain DNA repair genes as a mechanism to promote chemoresistance. Here, we report that RECQ1, a breast cancer susceptibility gene that encodes the most abundant RecQ helicase in humans, is a p53-regulated gene, potentially acting as a defense against DNA damaging agents. We show that RECQ1 mRNA and protein levels are upregulated upon treatment of cancer cells with a variety of DNA damaging agents including the DNA-alkylating agent methylmethanesulfonate (MMS)...
September 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28903444/early-tumour-shrinkage-as-a-survival-predictor-in-patients-with-recurrent-glioblastoma-treated-with-bevacizumab-in-the-avareg-randomized-phase-ii-study
#8
Alba A Brandes, Gaetano Finocchiaro, Vittorina Zagonel, Michele Reni, Alessandra Fabi, Claudia Caserta, Alicia Tosoni, Marica Eoli, Giuseppe Lombardi, Matteo Clavarezza, Alexandro Paccapelo, Stefania Bartolini, Luigi Cirillo, Raffaele Agati, Enrico Franceschi
BACKGROUND: Disease assessment for recurrent glioblastoma (GBM) represents a challenge, especially with the use of antiangiogenic agents. Moreover, validated neuroradiological predictors of outcome are lacking. Recently, the concept of early tumor shrinkage (ETS) has been developed to better assess the ability of treatments in determining a rapid and remarkable tumor response. The aim of the study was to evaluate the role of ETS in predicting survival of GBM patients treated with BEV...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28878924/serpentine-supravenous-hyperpigmentation
#9
Indirakshi Jamalpur, Harikrishna Reddy Mogili, Abhilash Koratala
Serpentine supravenous hyperpigmentation is a peculiar cutaneous eruption that follows the path of vein after intravenous injection of the chemotherapeutic agent. The lesions gradually resolve spontaneously if administration of the offending agent is stopped through the affected limb. Drugs such as 5-fluorouracil, docetaxel, vinorelbine, hydroxychloroquine, fotemustine, and minocycline are implicated.
September 2017: Clinical Case Reports
https://www.readbyqxmd.com/read/28656652/impressive-tissue-regeneration-of-severe-oral-mucositis-post-stem-cell-transplantation-using-cord-blood-platelet-gel
#10
Andrea Piccin, Paolo Rebulla, Simonetta Pupella, Mario Tagnin, Giuseppe Marano, Angela Maria Di Pierro, Michele Santodirocco, Lazzaro Di Mauro, Lisa Beqiri, Michael Kob, Marco Primerano, Marco Casini, Atto Billio, Klaus Eisendle, Fabrizio Fontanella
BACKGROUND: Platelet gel from cord blood (CBPG) is a recently developed blood component for topical use. We report a case of life-threatening mucositis after high-dose chemotherapy with fotemustine and cytarabine that was successfully treated with CBPG. CASE REPORT: A patient with non-Hodgkin lymphoma who was undergoing autologous hematopoietic stem cell transplantation developed severe oral and esophageal mucositis with severe bacterial sepsis and cytomegalovirus infection, causing prolonged neutropenia...
September 2017: Transfusion
https://www.readbyqxmd.com/read/28143714/chloroethylating-nitrosoureas-in-cancer-therapy-dna-damage-repair-and-cell-death-signaling
#11
REVIEW
Teodora Nikolova, Wynand P Roos, Oliver H Krämer, Herwig M Strik, Bernd Kaina
Chloroethylating nitrosoureas (CNU), such as lomustine, nimustine, semustine, carmustine and fotemustine are used for the treatment of malignant gliomas, brain metastases of different origin, melanomas and Hodgkin disease. They alkylate the DNA bases and give rise to the formation of monoadducts and subsequently interstrand crosslinks (ICL). ICL are critical cytotoxic DNA lesions that link the DNA strands covalently and block DNA replication and transcription. As a result, S phase progression is inhibited and cells are triggered to undergo apoptosis and necrosis, which both contribute to the effectiveness of CNU-based cancer therapy...
August 2017: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/28112719/the-role-of-the-cancer-stem-cell-marker-cd271-in-dna-damage-response-and-drug-resistance-of-melanoma-cells
#12
T Redmer, I Walz, B Klinger, S Khouja, Y Welte, R Schäfer, C Regenbrecht
Several lines of evidence have suggested that stemness and acquired resistance to targeted inhibitors or chemotherapeutics are mechanistically linked. Here we observed high cell surface and total levels of nerve growth factor receptor/CD271, a marker of melanoma-initiating cells, in sub-populations of chemoresistant cell lines. CD271 expression was increased in drug-sensitive cells but not resistant cells in response to DNA-damaging chemotherapeutics etoposide, fotemustine and cisplatin. Comparative analysis of melanoma cells engineered to stably express CD271 or a targeting short hairpin RNA by expression profiling provided numerous genes regulated in a CD271-dependent manner...
January 23, 2017: Oncogenesis
https://www.readbyqxmd.com/read/27815354/cytokine-induced-killer-cells-kill-chemo-surviving-melanoma-cancer-stem-cells
#13
Loretta Gammaitoni, Lidia Giraudo, Marco Macagno, Valeria Leuci, Giulia Mesiano, Ramona Rotolo, Francesco Sassi, Martina Sanlorenzo, Alessandro Zaccagna, Alberto Pisacane, Rebecca Senetta, Michela Cangemi, Giulia Cattaneo, Valentina Martin, Valentina Coha, Susanna Gallo, Ymera Pignochino, Anna Sapino, Giovanni Grignani, Fabrizio Carnevale-Schianca, Massimo Aglietta, Dario Sangiolo
Purpose: The MHC-unrestricted activity of cytokine-induced killer (CIK) cells against chemo-surviving melanoma cancer stem cells (mCSC) was explored, as CSCs are considered responsible for chemoresistance and relapses. Experimental Design: Putative mCSCs were visualized by engineering patient-derived melanoma cells (MC) with a lentiviral vector encoding eGFP under expression control by stemness gene promoter oct4 Their stemness potential was confirmed in vivo by limiting dilution assays. We explored the sensitivity of eGFP+ mCSCs to chemotherapy (CHT), BRAF inhibitor (BRAFi) or CIK cells, as single agents or in sequence, in vitro First, we treated MCs in vitro with fotemustine or dabrafenib (BRAF-mutated cases); then, surviving MCs, enriched in mCSCs, were challenged with autologous CIK cells...
May 1, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27474153/targeting-homologous-recombination-by-pharmacological-inhibitors-enhances-the-killing-response-of-glioblastoma-cells-treated-with-alkylating-drugs
#14
Nancy Berte, Andrea Piée-Staffa, Nadine Piecha, Mengwan Wang, Kerstin Borgmann, Bernd Kaina, Teodora Nikolova
Malignant gliomas exhibit a high level of intrinsic and acquired drug resistance and have a dismal prognosis. First- and second-line therapeutics for glioblastomas are alkylating agents, including the chloroethylating nitrosoureas (CNU) lomustine, nimustine, fotemustine, and carmustine. These agents target the tumor DNA, forming O6 -chloroethylguanine adducts and secondary DNA interstrand cross-links (ICL). These cross-links are supposed to be converted into DNA double-strand breaks, which trigger cell death pathways...
November 2016: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/27437102/prolonged-repeated-vaccine-immuno-chemotherapy-induces-long-term-clinical-responses-and-survival-for-advanced-metastatic-melanoma
#15
Brendon J Coventry, Carrie A Lilly, Peter Hersey, Antonio Michele, Richard J Bright
BACKGROUND: Repetitive long-term Vaccinia Melanoma Cell Lysate (VMCL) vaccination schedules have proved clinically effective in producing Complete Responses and strong durable survivals for up to 6.1 years in a previous study of patients with advanced Stage IV and Stage IIIc melanoma. These studies were expanded to include 54 patients for further evaluation of these findings. METHODS: 54 patients comprising 48 Stage IV (6 M1a, 14 M1b, 28 M1c) and 6 advanced Stage III (5 IIIc; 1 IIIb) were studied using repeated intra-dermal VMCL vaccine therapy...
2014: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/27418142/combined-vemurafenib-and-fotemustine-in-patients-with-brafv600-melanoma-progressing-on-vemurafenib
#16
Paola Queirolo, Francesco Spagnolo, Virginia Picasso, Laura Spano, Enrica Tanda, Valeria Fontana, Laura Giorello, Domenico Franco Merlo, Ester Simeone, Antonio Maria Grimaldi, Marcello Curvietto, Michele Del Vecchio, Paolo Bruzzi, Paolo Antonio Ascierto
BACKGROUND: BRAF inhibitor vemurafenib achieves high response rate and an improvement in survival in patients with BRAF-mutated metastatic melanoma. However, median progression-free survival is only 6.9 months in the phase 3 study. Retrospective analyses suggest that treatment with BRAF inhibitors beyond initial progression might be associated with improved overall survival. We aimed to prospectively investigate the activity of prolonged treatment with vemurafenib and the addition of fotemustine in patients with systemic progression on prior single-agent BRAF inhibitor...
July 13, 2016: Oncotarget
https://www.readbyqxmd.com/read/27347188/long-term-remission-of-subcutaneous-panniculitis-like-t-cell-lymphoma-with-central-nervous-system-involvement-a-case-report
#17
Yajuan Qiu, Dandan Zhang, Mingzhi Zhang
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is an indolent cutaneous T-cell lymphoma with a favourable prognosis. The reported incidence of central nervous system (CNS) involvement in SPTCL is extremely low. SPTCL with CNS involvement is a fatal disease with no optimal treatment. The present study presents the case of a 27-year-old man who initially presented with erythematous nodules on the left buttock and left inguinal lymph node enlargement. A skin biopsy resulted in a diagnosis of SPTCL. Subsequent to diagnosis, the patient developed CNS involvement and underwent treatment of fotemustine, teniposide and dexamethasone, and complete remission was achieved for 78 months...
July 2016: Oncology Letters
https://www.readbyqxmd.com/read/27202279/cost-effectiveness-analysis-of-bevacizumab-fotemustine-and-extended-dose-temozolomide-in-patients-with-recurrent-glioblastoma-in-spain
#18
J L Garcia Lopez, Barrios J M Rodriguez, J Puig-Junoy, Mena A Carrato
No abstract text is available yet for this article.
November 2014: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27165580/clinical-outcome-of-an-alternative-fotemustine-schedule-in-elderly-patients-with-recurrent-glioblastoma-a-mono-institutional-retrospective-study
#19
Giuseppe Lombardi, Luisa Bellu, Ardi Pambuku, Alessandro Della Puppa, Pasquale Fiduccia, Miriam Farina, Domenico D'Avella, Vittorina Zagonel
The optimal treatment of recurrent glioblastoma (GBM) in elderly patients is unclear. Fotemustine (FTM) is a third-generation nitrosourea showing efficacy in gliomas and it has been used with different schedules in adult patients. We performed, for the first time anywhere, a mono-institutional retrospective study to analyze the clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent GBM. Retrospectively, we analyzed all GBM patients 65 years or older previously treated with the combination of radiation therapy and temozolomide (TMZ), receiving an alternative FTM schedule as second-line treatment at our Oncological Center from October 2011 to October 2014 with an ECOG PS ≤ 2...
July 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27123564/cost-and-economic-burden-of-adverse-events-associated-with-metastatic-melanoma-treatments-in-five-countries
#20
Katja Vouk, Ursula Benter, Mayur M Amonkar, Alessia Marocco, Ceilidh Stapelkamp, Sylvie Pfersch, Laure Benjamin
OBJECTIVE: To estimate per-event cost and economic burden associated with managing the most common and/or severe metastatic melanoma (MM) treatment-related adverse events (AEs) in Australia, France, Germany, Italy, and the UK. METHODS: AEs associated with chemotherapy (dacarbazine, paclitaxel, fotemustine), immunotherapy (ipilimumab), and targeted therapy (vemurafenib) were identified by literature review. Medical resource use data associated with managing AEs were collected through two blinded Delphi panel cycles in each of the five countries...
September 2016: Journal of Medical Economics
keyword
keyword
166433
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"